triazoles has been researched along with Anxiety Neuroses in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (12.50) | 18.7374 |
| 1990's | 8 (33.33) | 18.2507 |
| 2000's | 10 (41.67) | 29.6817 |
| 2010's | 3 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Preskorn, SH | 1 |
| Arnow, BA; Gelenberg, AJ; Keller, ME; Klein, DN; Kocsis, JH; Kraemer, HC; Manber, R; Rothbaum, BO; Rush, AJ; Thase, ME; Trivedi, MH | 1 |
| Gehlert, DR; Iyengar, S; Kielbasa, W; Marek, G; Mozley, D; Peng, X; Tauscher, J; Vandenhende, F | 1 |
| Atack, JR | 1 |
| Bunck, M; Gaburro, S; Hauschild, M; Landgraf, R; Sartori, SB; Singewald, N | 1 |
| Basile, AS; Lippa, AS; Skolnick, P | 1 |
| Cassidy, EL; Lauderdale, S; Sheikh, JI | 1 |
| Bowman, FD; Ely, TD; Gordon, A; Gross, RE; Kelsey, JE; Kilts, CD; Knight, B; Nemeroff, CB; Newport, DJ; Selvig, A | 1 |
| Arnow, BA; Blasey, C; Constantino, MJ; Klein, DN; Kocsis, JH; Manber, R; Markowitz, JC; Rush, AJ; Thase, ME | 1 |
| Maletzky, BM | 1 |
| Anton, SF; Fawcett, J; Marcus, RN; O'Brien, K; Schwiderski, U | 1 |
| Zajecka, JM | 1 |
| Rothschild, AJ | 1 |
| DeMartinis, NA; Rickels, K; Schweizer, E | 1 |
| Halls, CH; Hedges, DW; Reimherr, FW; Rust, C; Strong, RE | 1 |
| Yonkers, KA | 1 |
| DeVane, CL; Grothe, DR; Smith, SL | 1 |
| Brady, KT; Charney, DS; Grothe, DR; Kaltsounis-Puckett, J; Laird, LK; Rush, AJ; Smith, SL; Wright, CW | 1 |
| Brunson, GH; Hales, RE; Hilty, DM | 1 |
| Borian, FE; Crits-Christoph, P; Keller, MB; Kornstein, SG; Manber, R; Ninan, PT; Rothbaum, BO; Rush, AJ; Thase, ME; Trivedi, MH; Zajecka, J | 1 |
| Copp, JE; Robinson, DS; Schwiderski, UE | 1 |
| Vinar, O | 1 |
| Antonelli, F; De Gregorio, M; Dionisio, A | 1 |
8 review(s) available for triazoles and Anxiety Neuroses
| Article | Year |
|---|---|
GABAA receptor alpha2/alpha3 subtype-selective modulators as potential nonsedating anxiolytics.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; GABA-A Receptor Agonists; Heterocyclic Compounds, 4 or More Rings; Humans; Hydrocarbons, Fluorinated; Pyridazines; Receptors, GABA-A; Treatment Outcome; Triazoles | 2010 |
Anxioselective anxiolytics: can less be more?
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepinones; Carbolines; Clinical Trials as Topic; Fluorobenzenes; GABA-A Receptor Agonists; Humans; Indoles; Pyrroles; Quinolones; Triazoles | 2004 |
Response of anxiety and agitation symptoms during nefazodone treatment of major depression.
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Comorbidity; Depressive Disorder; Double-Blind Method; Female; Humans; Imipramine; Male; Piperazines; Placebos; Psychomotor Agitation; Randomized Controlled Trials as Topic; Triazoles | 1995 |
The diagnosis and treatment of late-life depression.
Topics: Age Factors; Aged; Antidepressive Agents; Anxiety Disorders; Bupropion; Cyclohexanols; Depressive Disorder; Diagnosis, Differential; Electroconvulsive Therapy; Female; Humans; Lithium; Male; Monoamine Oxidase Inhibitors; Piperazines; Selective Serotonin Reuptake Inhibitors; Sex Factors; Trazodone; Triazoles; Venlafaxine Hydrochloride | 1996 |
Anxiety symptoms and anxiety disorders: how are they related to premenstrual disorders?
Topics: 1-Naphthylamine; Adult; Age of Onset; Anxiety; Anxiety Disorders; Buspirone; Carbon Dioxide; Comorbidity; Depressive Disorder; Diagnosis, Differential; Female; Humans; Mental Disorders; Panic Disorder; Piperazines; Premenstrual Syndrome; Psychotherapy; Risk Factors; Sertraline; Sodium Lactate; Triazoles | 1997 |
Pharmacology of antidepressants: focus on nefazodone.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Depressive Disorder; Drug Interactions; Humans; Piperazines; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sleep; Triazoles | 2002 |
Overview of psychiatric disorders and the role of newer antidepressants.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Depressive Disorder; Humans; Mental Disorders; Piperazines; Sleep Wake Disorders; Triazoles | 2002 |
Cost savings with nefazodone in treating depression.
Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cost Savings; Depressive Disorder; Drug Costs; Drug Therapy, Combination; Health Care Costs; Humans; Hypnotics and Sedatives; Piperazines; Sleep Wake Disorders; Triazoles | 2002 |
11 trial(s) available for triazoles and Anxiety Neuroses
| Article | Year |
|---|---|
Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder.
Topics: Adult; Animals; Anti-Anxiety Agents; Anxiety Disorders; Brain; Dose-Response Relationship, Drug; Gerbillinae; Humans; Male; Neurokinin-1 Receptor Antagonists; Paroxetine; Peptide Fragments; Pyridines; Radioligand Assay; Radionuclide Imaging; Receptors, Neurokinin-1; Stereotyped Behavior; Substance P; Treatment Outcome; Triazoles | 2010 |
Mixed anxiety and depression in older adults: clinical characteristics and management.
Topics: Aged; Aging; Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depressive Disorder, Major; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Treatment Outcome; Triazoles | 2005 |
The neural correlates of social anxiety disorder and response to pharmacotherapy.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety Disorders; Brain; Brain Mapping; Case-Control Studies; Cerebrovascular Circulation; Female; Humans; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Regional Blood Flow; Social Behavior Disorders; Statistics as Topic; Triazoles | 2006 |
Dropouts versus completers among chronically depressed outpatients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Anxiety Disorders; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Patient Dropouts; Physician-Patient Relations; Piperazines; Risk Factors; Triazoles | 2007 |
Anxiolytic efficacy of alprazolam compared to diazepam and placebo.
Topics: Adolescent; Adult; Aged; Alprazolam; Anti-Anxiety Agents; Anxiety Disorders; Benzodiazepines; Clinical Trials as Topic; Diazepam; Double-Blind Method; Humans; Middle Aged; Placebos; Psychiatric Status Rating Scales; Triazoles | 1980 |
The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings.
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Anxiety Disorders; Community Mental Health Services; Comorbidity; Depressive Disorder; Drug Administration Schedule; Family Practice; Female; Humans; Imipramine; Male; Middle Aged; Personality Inventory; Piperazines; Placebos; Psychiatric Status Rating Scales; Retrospective Studies; Treatment Outcome; Triazoles | 1996 |
An open-label trial of nefazodone in high comorbidity panic disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depression; Depressive Disorder; Female; Humans; Male; Middle Aged; Panic Disorder; Piperazines; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome; Triazoles | 1996 |
An open trial of nefazodone in adult patients with generalized anxiety disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Triazoles | 1996 |
Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Depressive Disorder; Drug Administration Schedule; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Treatment Outcome; Triazoles | 2002 |
Symptom comorbidity in anxiety and depressive disorders.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Buspirone; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Panic; Personality Assessment; Piperazines; Psychometrics; Pyrimidines; Randomized Controlled Trials as Topic; Triazoles | 1990 |
Trazodone in the treatment of psychoneuroses: a double-blind study.
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Conversion Disorder; Female; Humans; Male; Middle Aged; Neurotic Disorders; Obsessive-Compulsive Disorder; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychomotor Disorders; Psychophysiologic Disorders; Pyridines; Sleep Wake Disorders; Time Factors; Triazoles | 1973 |
5 other study(ies) available for triazoles and Anxiety Neuroses
| Article | Year |
|---|---|
How multiple medication use evolves and the importance of therapeutic trials: the slippery slide.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Asthma; Bronchodilator Agents; Buspirone; Clozapine; Comorbidity; Cooperative Behavior; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Humans; Long-Term Care; Patient Care Team; Piperazines; Referral and Consultation; Schizophrenia; Schizophrenic Psychology; Theophylline; Triazoles | 2008 |
Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Chronic Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Remission Induction; ROC Curve; Severity of Illness Index; Time Factors; Triazoles | 2008 |
Enhanced fear expression in a psychopathological mouse model of trait anxiety: pharmacological interventions.
Topics: Animals; Anti-Anxiety Agents; Anxiety Disorders; Behavior, Animal; Corticosterone; Disease Models, Animal; Disease Progression; Drug Evaluation, Preclinical; Expressed Emotion; Fear; Fluorobenzenes; Male; Mice; Neurokinin-1 Receptor Antagonists; Phobic Disorders; Physical Conditioning, Animal; Piperidines; Psychopathology; Triazoles; Up-Regulation | 2011 |
New perspectives in the management of depression. Symposium highlights from ECNP, Venice, September 1995.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depressive Disorder; Humans; Imipramine; Piperazines; Triazoles | 1996 |
Introductory remarks: new agents in psychiatry.
Topics: Antidepressive Agents; Anxiety Disorders; Depression; Humans; Mental Disorders; Piperazines; Pyridines; Schizophrenia; Triazoles; United States; United States Food and Drug Administration | 1973 |